南京艾美斐生物医药科技有限公司

公司简介

南京艾美斐生物医药科技有限公司2016年于南京浦口区成立，研发中心坐落在上海漕河泾开发区浦江高科技园，是一家专注于新药创制的高新技术企业，公司聚焦于恶性肿瘤、自身免疫性、神经退行性等重大疾病，从免疫调节等环节入手开展新药研发。目前在研产品管线丰富，有巨噬细胞移动抑制因子（MIF）小分子抑制剂、赖氨酸特异性去甲基化酶 1（LSD1）小分子抑制剂、CXCR2小分子拮抗剂、抗络氨酸激酶孤儿受体（ROR1）嵌合抗原受体T细胞技术等。公司高度注重原创性药物研发，从源头创新，确保行业领域的优势地位。公司拥有着资深海归科学家组成的核心团队，在医学、药理学、药物化学、药代动力学、生物靶标等领域皆处于国际一流水平；技术上公司拥有表型筛选技术平台、转化医学研究平台、化合物构效关系研究平台、CAR-T技术研究平台，为药物研发科技创新奠定了坚实的基础。以现代生物技术为主要依托、以科技创新为主要驱动力，艾美斐致力于5-8年内，达到1-2个创新药成功上市的目标，形成具有丰富研发管线、在国内名列前茅、在国际上有相当知名度的高科技药物公司。Nanjing Immunophage Biotech Co. Ltd. is a high-tech pharmaceutic company which was established in 2016 in Pukou district, Nanjing, China. The R&D center of the company is located in the Pujiang High-Tech Park,Shanghai, China. We are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases,neurodegenerative disorders. The advanced projects in our pipeline include small molecule inhibitors for macrophage migration inhibitory factor （MIF）, small molecule inhibitors for lysine specific demethylase 1 (LSD1),anti-ROR1 chemoeric antigen receptor T cell (CAR-T). We are innovating from origin to ensure our leading position in the field.The founders of the company are scientists being trained in US with over 20 years of research experience in medicine,pharmacology, medicinal chemistry, and biomarkers. We possess multiple drug discovery platforms, including phenotypic screening platform, translational medicine platform, structural-activity relationship platform, CAR-T platform, which ensure high level drug discovery activities. Based on advanced biological technology, we aim to produce 1-2 novel medicines in 5-8 years.